CN1158277C
(en)
*
|
1998-02-02 |
2004-07-21 |
Lg化学株式会社 |
Farnesyl transferase inhibitors having a piperidine structure and process for preparation thereof
|
US6331541B1
(en)
|
1998-12-18 |
2001-12-18 |
Soo S. Ko |
N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
|
US6525069B1
(en)
|
1998-12-18 |
2003-02-25 |
Bristol-Myers Squibb Pharma Co. |
N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
|
DE69926919D1
(en)
|
1998-12-18 |
2005-09-29 |
Bristol Myers Squibb Pharma Co |
N-UREIDOALKYLPIPERIDINES AS MODULATORS OF THE ACTIVITY OF CHEMOKIN RECEPTORS
|
CA2347770A1
(en)
|
1998-12-18 |
2000-06-22 |
Bristol-Myers Squibb Pharma Company |
N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
|
US6897234B2
(en)
|
1999-12-17 |
2005-05-24 |
Bristol-Myers Squibb Pharma Company |
N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
|
KR100879647B1
(en)
*
|
2000-03-06 |
2009-01-20 |
아카디아 파마슈티칼스 인코포레이티드 |
Azacyclic compounds for use in the treatment of serotonin related diseases
|
IL153123A0
(en)
|
2000-06-30 |
2003-06-24 |
Bristol Myers Squibb Co |
N-ureidoheterocycloalkyl-piperidine derivatives and pharmaceutical compositions containing the same
|
FR2819511A1
(en)
*
|
2001-01-18 |
2002-07-19 |
Servier Lab |
New N-substituted azepane or azepanone derivatives, are selective farnesyl transferase inhibitors useful for treating cancer diseases, restenosis or type I neurofibromatosis
|
FR2819510B1
(en)
*
|
2001-01-18 |
2003-10-31 |
Servier Lab |
NOVEL CYCLO [C] AZEPANE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
|
FR2819512B1
(en)
*
|
2001-01-18 |
2003-02-21 |
Servier Lab |
NOVEL CYCLO [D] AZEPANE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
|
FR2819509B1
(en)
*
|
2001-01-18 |
2004-04-16 |
Servier Lab |
NOVEL CYCLOHEPTENE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
|
MXPA03009600A
(en)
*
|
2001-04-18 |
2004-04-02 |
Euro Celtique Sa |
Nociceptin analogs.
|
US6624162B2
(en)
|
2001-10-22 |
2003-09-23 |
Pfizer Inc. |
Imidazopyridine compounds as 5-HT4 receptor modulators
|
MXPA04006280A
(en)
|
2001-12-28 |
2004-09-27 |
Acadia Pharm Inc |
Spiroazacyclic compounds as monoamine receptor modulators.
|
MXPA03000145A
(en)
|
2002-01-07 |
2003-07-15 |
Pfizer |
Oxo or oxy-pyridine compounds as 5-ht4 receptor modulators.
|
ES2193875B2
(en)
|
2002-04-09 |
2005-03-01 |
Laboratorios Del Dr. Esteve, S.A. |
DERIVATIVES OF BENZOXAZINONA, ITS PREPARATION AND ITS APPLICATION AS MEDICATIONS.
|
GB0211230D0
(en)
|
2002-05-16 |
2002-06-26 |
Medinnova Sf |
Treatment of heart failure
|
US7253186B2
(en)
|
2002-06-24 |
2007-08-07 |
Carl-Magnus Andersson |
N-substituted piperidine derivatives as serotonin receptor agents
|
US7538222B2
(en)
|
2002-06-24 |
2009-05-26 |
Acadia Pharmaceuticals, Inc. |
N-substituted piperidine derivatives as serotonin receptor agents
|
AU2003247615B2
(en)
|
2002-06-24 |
2007-08-09 |
Acadia Pharmaceuticals Inc. |
N-substituted piperidine derivatives as serotonin receptor agents
|
TW200409637A
(en)
|
2002-06-26 |
2004-06-16 |
Glaxo Group Ltd |
Compounds
|
DOP2003000703A
(en)
|
2002-09-20 |
2004-03-31 |
Pfizer |
IMIDAZOPIRADINE COMPOUNDS AS 5-HT4 RECEIVER AGONISTS
|
CA2499494A1
(en)
|
2002-09-20 |
2004-04-01 |
Pfizer Inc. |
N-substituted piperidinyl-imidazopyridine compounds as 5-ht4 receptor modulators
|
US6919356B2
(en)
|
2002-09-26 |
2005-07-19 |
Bristol Myers Squibb Company |
N-substituted heterocyclic amines as modulators of chemokine receptor activity
|
ES2314362T3
(en)
|
2003-01-16 |
2009-03-16 |
Acadia Pharmaceuticals Inc. |
SELECTIVE INVESTING AGONISTS OF SEROTONINE 2A OR 2C RECEPTORS USED AS THERAPEUTIC AGENTS AGAINST NEURODEGENERATIVE DISEASES.
|
CN1829708A
(en)
|
2003-07-24 |
2006-09-06 |
尤罗塞尔蒂克股份有限公司 |
Piperidine compounds and pharmaceutical compositions containing them
|
US20050261278A1
(en)
|
2004-05-21 |
2005-11-24 |
Weiner David M |
Selective serotonin receptor inverse agonists as therapeutics for disease
|
US7820695B2
(en)
|
2004-05-21 |
2010-10-26 |
Acadia Pharmaceuticals, Inc. |
Selective serotonin receptor inverse agonists as therapeutics for disease
|
EA200801608A1
(en)
|
2004-06-15 |
2008-10-30 |
Пфайзер Инк. |
DERIVATIVES OF BENZIMIDAZOLONIC CARBONIC ACID
|
US7737163B2
(en)
|
2004-06-15 |
2010-06-15 |
Pfizer Inc. |
Benzimidazolone carboxylic acid derivatives
|
CN101031548B
(en)
|
2004-09-27 |
2011-04-06 |
阿卡蒂亚药品公司 |
Salts of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy) phenylmethyl) carbamide and their preparation
|
US7790899B2
(en)
|
2004-09-27 |
2010-09-07 |
Acadia Pharmaceuticals, Inc. |
Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
|
MY179032A
(en)
|
2004-10-25 |
2020-10-26 |
Cancer Research Tech Ltd |
Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
|
UY29177A1
(en)
|
2004-10-25 |
2006-05-31 |
Astex Therapeutics Ltd |
SUBSTITUTED DERIVATIVES OF PURINA, PURINONA AND DEAZAPURINA, COMPOSITIONS THAT CONTAIN METHODS FOR THEIR PREPARATION AND ITS USES
|
US8362075B2
(en)
|
2005-05-17 |
2013-01-29 |
Merck Sharp & Dohme Corp. |
Cyclohexyl sulphones for treatment of cancer
|
US7576106B2
(en)
|
2005-10-11 |
2009-08-18 |
Chemocentryx, Inc. |
Piperidine derivatives and methods of use
|
US7601844B2
(en)
|
2006-01-27 |
2009-10-13 |
Bristol-Myers Squibb Company |
Piperidinyl derivatives as modulators of chemokine receptor activity
|
US7615556B2
(en)
|
2006-01-27 |
2009-11-10 |
Bristol-Myers Squibb Company |
Piperazinyl derivatives as modulators of chemokine receptor activity
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
US8796293B2
(en)
|
2006-04-25 |
2014-08-05 |
Astex Therapeutics Limited |
Purine and deazapurine derivatives as pharmaceutical compounds
|
WO2008039327A2
(en)
|
2006-09-22 |
2008-04-03 |
Merck & Co., Inc. |
Method of treatment using fatty acid synthesis inhibitors
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
PL2336120T3
(en)
|
2007-01-10 |
2014-12-31 |
Msd Italia Srl |
Combinations containing amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
|
MX2009009304A
(en)
|
2007-03-01 |
2009-11-18 |
Novartis Ag |
Pim kinase inhibitors and methods of their use.
|
JP2010522198A
(en)
|
2007-03-19 |
2010-07-01 |
アカドイア プハルマセウチカルス インコーポレーテッド |
Combination of 5-HT2A inverse agonists and antagonists with antipsychotics
|
WO2008120759A1
(en)
*
|
2007-03-30 |
2008-10-09 |
Japan Tobacco Inc. |
Urea compound and use thereof
|
ES2571533T3
(en)
|
2007-04-27 |
2016-05-25 |
Purdue Pharma Lp |
TRPV1 antagonists and uses thereof
|
EP2091936B1
(en)
|
2007-04-27 |
2013-05-15 |
Purdue Pharma LP |
Therapeutic agents useful for treating pain
|
CA2685967A1
(en)
|
2007-05-21 |
2008-11-21 |
Novartis Ag |
Csf-1r inhibitors, compositions, and methods of use
|
CA2690191C
(en)
|
2007-06-27 |
2015-07-28 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
WO2009011872A1
(en)
|
2007-07-17 |
2009-01-22 |
Merck & Co., Inc. |
Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment
|
RS53552B1
(en)
|
2007-10-11 |
2015-02-27 |
Astrazeneca Ab |
Pyrrolo[2,3-d]pyrimidin derivatives as protein kinase b inhibitors
|
TWI433838B
(en)
|
2008-06-25 |
2014-04-11 |
必治妥美雅史谷比公司 |
Piperidinyl derivative as a modulator of chemokine receptor activity
|
US9540322B2
(en)
|
2008-08-18 |
2017-01-10 |
Yale University |
MIF modulators
|
BRPI0917394A2
(en)
*
|
2008-08-18 |
2019-09-24 |
Univ Yale |
mif modulators
|
US9643922B2
(en)
|
2008-08-18 |
2017-05-09 |
Yale University |
MIF modulators
|
WO2010114780A1
(en)
|
2009-04-01 |
2010-10-07 |
Merck Sharp & Dohme Corp. |
Inhibitors of akt activity
|
US8765747B2
(en)
|
2009-06-12 |
2014-07-01 |
Dana-Farber Cancer Institute, Inc. |
Fused 2-aminothiazole compounds
|
PE20121172A1
(en)
|
2009-10-14 |
2012-09-05 |
Merck Sharp & Dohme |
PIPERIDINS SUBSTITUTED WITH ACTIVITY IN HDM2
|
US9180127B2
(en)
|
2009-12-29 |
2015-11-10 |
Dana-Farber Cancer Institute, Inc. |
Type II Raf kinase inhibitors
|
WO2011093365A1
(en)
*
|
2010-01-27 |
2011-08-04 |
協和発酵キリン株式会社 |
Nitrogenated heterocyclic compound
|
BR112012023021A2
(en)
|
2010-03-16 |
2016-05-31 |
Dana Farber Cancer Inst Inc |
indazole compounds and their uses
|
US8642622B2
(en)
|
2010-06-16 |
2014-02-04 |
Bristol-Myers Squibb Company |
Piperidinyl compound as a modulator of chemokine receptor activity
|
US8921373B2
(en)
|
2010-06-22 |
2014-12-30 |
Shionogi & Co., Ltd. |
Compounds having TRPV1 antagonistic activity and uses thereof
|
US8999957B2
(en)
|
2010-06-24 |
2015-04-07 |
Merck Sharp & Dohme Corp. |
Heterocyclic compounds as ERK inhibitors
|
CA2805265A1
(en)
|
2010-08-02 |
2012-02-09 |
Merck Sharp & Dohme Corp. |
Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
|
CA2807307C
(en)
|
2010-08-17 |
2021-02-09 |
Merck Sharp & Dohme Corp. |
Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
|
EP2608669B1
(en)
|
2010-08-23 |
2016-06-22 |
Merck Sharp & Dohme Corp. |
NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
|
US8946216B2
(en)
|
2010-09-01 |
2015-02-03 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as ERK inhibitors
|
US9242981B2
(en)
|
2010-09-16 |
2016-01-26 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel ERK inhibitors
|
EP2632472B1
(en)
|
2010-10-29 |
2017-12-13 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
|
US8980924B2
(en)
|
2010-11-24 |
2015-03-17 |
The Trustees Of Columbia University In The City Of New York |
Non-retinoid RBP4 antagonist for treatment of age-related macular degeneration and stargardt disease
|
US9351965B2
(en)
|
2010-12-21 |
2016-05-31 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as ERK inhibitors
|
CA2831848C
(en)
|
2011-04-01 |
2020-12-22 |
Astrazeneca Ab |
Combination comprising (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide and a taxane
|
IN2013MN02170A
(en)
|
2011-04-21 |
2015-06-12 |
Piramal Entpr Ltd |
|
GB201106817D0
(en)
|
2011-04-21 |
2011-06-01 |
Astex Therapeutics Ltd |
New compound
|
RU2621708C2
(en)
|
2011-06-22 |
2017-06-07 |
ПУРДЬЮ ФАРМА Эл. Пи. |
Antagonists of trpv1, containing dihydroxy group as substitute, and their use
|
AU2012293417A1
(en)
|
2011-08-10 |
2013-05-02 |
Purdue Pharma L.P. |
TRPV1 antagonists including dihydroxy substituent and uses thereof
|
WO2013063214A1
(en)
|
2011-10-27 |
2013-05-02 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
EP3569598A1
(en)
|
2011-11-17 |
2019-11-20 |
Dana Farber Cancer Institute, Inc. |
Inhibitors of c-jun-n-terminal kinase (jnk)
|
FI2785349T4
(en)
|
2011-11-30 |
2023-02-09 |
|
Combination treatment of cancer
|
WO2013112323A1
(en)
*
|
2012-01-23 |
2013-08-01 |
Eli Lilly And Company |
Phenyl methanesulfonamide derivatives useful as mgat - 2 inhibitors
|
AU2013204533B2
(en)
|
2012-04-17 |
2017-02-02 |
Astrazeneca Ab |
Crystalline forms
|
US9333202B2
(en)
|
2012-05-01 |
2016-05-10 |
The Trustees Of Columbia University In The City Of New York |
Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease
|
EP2844261B1
(en)
|
2012-05-02 |
2018-10-17 |
Sirna Therapeutics, Inc. |
SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
|
WO2014052563A2
(en)
|
2012-09-28 |
2014-04-03 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
EP2909194A1
(en)
|
2012-10-18 |
2015-08-26 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
WO2014063054A1
(en)
|
2012-10-19 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
|
US9980973B2
(en)
|
2012-10-19 |
2018-05-29 |
Astex Therapeutics Limited |
Bicyclic heterocycle compounds and their uses in therapy
|
GB201218862D0
(en)
|
2012-10-19 |
2012-12-05 |
Astex Therapeutics Ltd |
Bicyclic heterocycle compounds and their uses in therapy
|
GB201218864D0
(en)
|
2012-10-19 |
2012-12-05 |
Astex Therapeutics Ltd |
Bicyclic heterocycle compounds and their uses in therapy
|
GB201218850D0
(en)
|
2012-10-19 |
2012-12-05 |
Astex Therapeutics Ltd |
Bicyclic heterocycle compounds and their uses in therapy
|
WO2014063061A1
(en)
|
2012-10-19 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
MX363243B
(en)
|
2012-11-28 |
2019-03-14 |
Merck Sharp & Dohme |
Compositions and methods for treating cancer.
|
BR112015013611A2
(en)
|
2012-12-20 |
2017-11-14 |
Merck Sharp & Dohme |
compound and pharmaceutical composition
|
EP2951180B1
(en)
|
2013-01-30 |
2018-05-02 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as hdm2 inhibitors
|
ES2705247T3
(en)
|
2013-03-14 |
2019-03-22 |
Univ Columbia |
4-phenylpiperidines, their preparation and use
|
US9637450B2
(en)
|
2013-03-14 |
2017-05-02 |
The Trustees Of Columbia University In The City Of New York |
Octahydrocyclopentapyrroles, their preparation and use
|
WO2014151959A1
(en)
|
2013-03-14 |
2014-09-25 |
The Trustees Of Columbia University In The City Of New York |
N-alkyl-2-phenoxyethanamines, their preparation and use
|
US9944644B2
(en)
|
2013-03-14 |
2018-04-17 |
The Trustees Of Columbia University In The City Of New York |
Octahydropyrrolopyrroles their preparation and use
|
EP3041938A1
(en)
|
2013-09-03 |
2016-07-13 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
ES2676734T3
(en)
|
2013-10-18 |
2018-07-24 |
Syros Pharmaceuticals, Inc. |
Heteroatomic compounds useful for the treatment of proliferative diseases
|
AU2014337044A1
(en)
|
2013-10-18 |
2016-05-05 |
Dana-Farber Cancer Institute, Inc. |
Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
|
CA2933939C
(en)
|
2013-12-20 |
2021-03-16 |
Astex Therapeutics Limited |
Bicyclic heterocycle compounds and their uses in therapy
|
US10017477B2
(en)
|
2014-04-23 |
2018-07-10 |
Dana-Farber Cancer Institute, Inc. |
Janus kinase inhibitors and uses thereof
|
WO2015164604A1
(en)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged janus kinase inhibitors and uses thereof
|
CN111393434B
(en)
|
2014-04-30 |
2022-11-04 |
哥伦比亚大学董事会 |
Substituted 4-phenylpiperidines, their preparation and use
|
JO3589B1
(en)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
Protein kinase c inhibitors and methods of their use
|
JP6854762B2
(en)
|
2014-12-23 |
2021-04-07 |
ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド |
Inhibitor of cyclin-dependent kinase 7 (CDK7)
|
JP6861166B2
(en)
|
2015-03-27 |
2021-04-21 |
ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド |
Inhibitor of cyclin-dependent kinase
|
AU2016276963C1
(en)
|
2015-06-12 |
2021-08-05 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
CN107848972B
(en)
|
2015-07-20 |
2021-06-18 |
阿卡蒂亚药品公司 |
Process for the preparation of N- (4-fluorobenzyl) -N- (1-methylpiperidin-4-yl) -N' - (4- (2-methylpropyloxy) phenylmethyl) urea and its tartrate salt and polymorph C
|
CA2996978A1
(en)
|
2015-09-09 |
2017-03-16 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
WO2017165635A1
(en)
|
2016-03-25 |
2017-09-28 |
Acadia Pharmaceuticals Inc. |
Combination of pimavanserin and cytochrome p450 modulators
|
US10953000B2
(en)
|
2016-03-25 |
2021-03-23 |
Acadia Pharmaceuticals Inc. |
Combination of pimavanserin and cytochrome P450 modulators
|
JOP20190055A1
(en)
|
2016-09-26 |
2019-03-24 |
Merck Sharp & Dohme |
Anti-cd27 antibodies
|
EP3558311A1
(en)
|
2016-12-20 |
2019-10-30 |
Acadia Pharmaceuticals Inc. |
Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis
|
MX2019012233A
(en)
|
2017-04-13 |
2020-01-14 |
Aduro Biotech Holdings Europe Bv |
Anti-sirp alpha antibodies.
|
WO2018200977A1
(en)
|
2017-04-28 |
2018-11-01 |
Acadia Pharmaceuticals Inc. |
Pimavanserin for treating impulse control disorder
|
WO2019046167A1
(en)
|
2017-08-30 |
2019-03-07 |
Acadia Pharmaceuticals Inc. |
Formulations of pimavanserin
|
WO2019094311A1
(en)
|
2017-11-08 |
2019-05-16 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
WO2019148412A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1/lag3 bispecific antibodies
|
US20210277009A1
(en)
|
2018-08-07 |
2021-09-09 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
WO2020033284A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
WO2023156386A2
(en)
*
|
2022-02-16 |
2023-08-24 |
Duke Street Bio Limited |
Pharmaceutical compound
|